CD8A and neoplasm: Compared to naïve mice (PBS group), RBC‐Nanovaccine vaccinated mice exhibited a 1.5‐fold higher percentage of CD8+ memory T cells (CD8+CD44high), which can be reactivated upon the secondary tumor challenge (Fig 4G and H).